<DOC>
	<DOCNO>NCT01811277</DOCNO>
	<brief_summary>This exploratory , single-armed , open label study efficacy safety sequential S-1 therapy SOX unresectable metastatic locally advanced biliary system periampullary cancer pancreatic cancer patient . The primary endpoint Objective response rate secondary endpoint progression free survival , overall survival ,1 year survival rate safety .</brief_summary>
	<brief_title>SOX Sequential S-1 Advanced Biliary Tract Carcinoma（BTC）and Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Written Informed consent Male female patient &gt; =18 year old Histologically cytologically confirm diagnosis adenocarcinoma No previous treatment allow include chemotherapy , radiotherapy , immunotherapy others . In case patient receive adjuvant therapy , enrollment allow adjuvant therapy contain LOHP S1 time , last day chemotherapy ≥180 day screen . Target lesion 1cm diameter enhance CT MRI 21 day enrollment The laboratory parameter meet follow criterion 7 day enrollment Hemoglobin ≥90g/L Absolute neutrophil count≥1.5×10^9/L , platelets 100×10^9/L； ALT AST≤2.5 ULN ( case patient liver metastasis , ALT AST≤5.0 ULN ) ALP ≤2.5 ULN ( case patient liver metastasis , ≤5.0 ULN ) Total Serum bilirubin ≤1.5 ULN Serum creatinine ≤1.0 ULN serum albumin ( ALB ) ≥30g/L； tolerate oral drug administration； KPS ≥70 Estimated survival ≥90 day Women childbearing potential must negative serum urine pregnancy test within 7 day enrollment must willing use adequate method contraception study 30 day last study durg administration . Known sensitivity 5HT3 antagonist hypersensitivity treatment agent include irinotecan , cisplatin octreotide lar Any participation trial simultaneously 4 week screen . 15 day prior enrollment , receive blood transfusion , blood product hematopoietic growth factor GCSF . Undergone major surgery ≤ 4 week prior start study drug recover side effect surgery . Uncontrolled severe diarrhea Uncontrolled active infection ( fever ≥38 degree due infection ) S1 oral drug administration difficulty due difficulty swallowing , complete incomplete digestive tract obstruction , gastrointestinal active bleeding , perforation ; severe hepatopathy include active hepatitis hepatic cirrhosis , renal dysfunction , severe pulmonary disease include interstitial pneumonia , pulmonary fibrosis severe pulmonary emphysema , uncontrolled diabetes , hypertension chronic systematic disease . Chronic treatment steroid . ( In case patient shortterm use steroid , enrollment permit administration stop 2 week screen . ) confirm suspected CNS metastasis history peripheral nervous system impairment , obvious mental disorder CNS impairment clinically significant heart disease , include congestive heart failure , symptomatic coronal heart disease , arrythmia uncontrolled medication acute myocardial infarction cardiac insufficiency within 6 month screen Drainage pleural effusion , peritoneal effusion pericardial effusion pregnant woman woman lactation period Fertile male woman childbearing potential refuse take highly effective method birth control Incidence second primary malignant tumor within 5 year , except cure basal cell carcinoma cervical carcinoma situ . patient legal incapacity potential influence whole trial due medical ethic reason . Other patient eligible trial investigator ' discretion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>palliative chemotherapy</keyword>
	<keyword>ORR</keyword>
	<keyword>PFS</keyword>
	<keyword>OS</keyword>
	<keyword>safety</keyword>
	<keyword>advanced Biliary Tract Carcinoma</keyword>
</DOC>